Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ad/PNP · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Ad/PNP | BIOLOGICAL | Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase |
| Fludarabine Phosphate | DRUG | Fludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia. |
Top 20 of 58 competitors
Ad/PNP is an investigational therapy being studied for the treatment of recurrent head and neck cancer. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being evaluated in a completed Phase 1/Phase 2 clinical trial.
Ad/PNP is being developed by GeoVax Labs, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GOVX. The company is conducting clinical research to evaluate the safety and efficacy of Ad/PNP in patients with recurrent head and neck cancer.
Ad/PNP is in Phase 2 clinical development, specifically having completed a Phase 1/Phase 2 trial. The drug remains investigational and is not yet approved for commercial use. The completed trial enrolled 10 patients with recurrent head and neck cancer.
Ad/PNP has been studied in one clinical trial registered as NCT03754933, titled 'Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer.' This Phase 1/Phase 2 trial has been completed and enrolled 10 participants with recurrent head and neck cancer.
Ad/PNP is not FDA approved. It is an investigational drug currently in clinical development for recurrent head and neck cancer. The drug has completed a Phase 1/Phase 2 clinical trial, but it has not received regulatory approval for any indication.